Hyderabad: The growth trajectory for Indian pharmaceutical industry is likely to be moderate, in single digit on the back of slowing growth from US given the relatively moderate proportion of large size drugs going off patent, increased competition leading to price erosion in low double digit, generic ...
Read more: Pharma revenues from US dipping, says ICRA